848846-84-4Relevant articles and documents
Discovery of new orally active prostaglandin D2 receptor antagonists
Iwahashi, Maki,Naganawa, Atsushi,Kinoshita, Atsushi,Shimabukuro, Atsushi,Nishiyama, Toshihiko,Ogawa, Seiji,Matsunaga, Yoko,Tsukamoto, Kohki,Okada, Yutaka,Matsumoto, Ryoji,Nambu, Fumio,Oumi, Rie,Odagaki, Yoshihiko,Katagi, Jun,Yano, Koji,Tani, Kousuke,Nakai, Hisao,Toda, Masaaki
, p. 6935 - 6948 (2012/01/05)
To identify an orally available drug candidate, a series of 3-benzoylaminophenylacetic acids were synthesized and evaluated as prostaglandin D2 (PGD2) receptor antagonists. Some of the compounds tested were found to exhibit excellent
CARBOXYLIC ACID COMPOUNDS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT
-
Page/Page column 57, (2008/06/13)
A compound represented by formula (I) wherein the symbols in the formula are the same meanings as those in specification, salts thereof, solvates thereof, or prodrugs thereof binds to DP receptor and shows antagonistic activity for DP receptor. Thus, it is useful for prevention and/or treatment of diseases such as allergic disease (e.g., allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, urticaria, eczema, diseases accompanied by itch (e.g., atopic dermatitis and urticaria), diseases (e.g., cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (e.g., scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy ulcerative colitis, etc. Since it specifically binds to DP receptor and binds weakly to other prostaglandins receptors, they can be pharmaceuticals having little side effect.
